IQVIA Holdings Inc (IQV) FinancialsIQVFinancialIQVIA Holdings Inc

IQVIA Holdings Inc. (IQV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Research & Development Solutions, accounting for 59.0% of total sales, equivalent to $2.58B. Another important revenue stream is Commercial Solutions. Understanding this composition is critical for investors evaluating how IQV navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, IQVIA Holdings Inc. maintains a gross margin of 26.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.03%, while the net margin is 5.91%. These profitability ratios, combined with a Return on Equity (ROE) of 23.01%, provide a clear picture of how effectively IQV converts its operational activities into shareholder value.

In the context of the broader market, IQV competes directly with industry leaders such as NTRA and MRNA. With a market capitalization of $38.95B, it holds a significant position in the sector. When comparing efficiency, IQV's gross margin of 26.17% stands against NTRA's 63.70% and MRNA's 64.14%. Such benchmarking helps identify whether IQVIA Holdings Inc. is trading at a premium or discount relative to its financial performance.

IQVIA has demonstrated strong financial performance with a 1-year change of +42.46% and a gross margin of 26.17% in Q2 2026, indicating solid profitability.